Alluvi, formerly LY3414901, represents a significant advancement in metabolic management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist shows remarkable efficacy in early medical data, with considerable reduction in weight … Read More